AMGEN INC (AMG.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:AMG - US0311621009 - Common Stock
AMG.DE Key Statistics, Chart & Performance
The current stock price of AMG.DE is 295.4 EUR. In the past month the price increased by 16.46%. In the past year, price increased by 10.27%.
AMG.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 74.26 | 49.11B | ||
| ARGX.BR | ARGENX SE | 73.63 | 48.69B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.12B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.70B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.64B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.76B | ||
| 5CV.DE | CUREVAC NV | 5.36 | 1.05B | ||
| NANO.PA | NANOBIOTIX | N/A | 845.70M | ||
| PHIL.MI | PHILOGEN SPA | 21.05 | 701.76M | ||
| IVA.PA | INVENTIVA SA | N/A | 546.97M | ||
| ALCLS.PA | CELLECTIS | N/A | 445.95M | ||
| FYB.DE | FORMYCON AG | N/A | 434.68M |
Related stock screener links
About AMG.DE
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Company Info
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA US
Employees: 28000
Phone: 18054471000
AMGEN INC / AMG.DE FAQ
What does AMGEN INC do?
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
What is the stock price of AMGEN INC today?
The current stock price of AMG.DE is 295.4 EUR. The price decreased by -0.19% in the last trading session.
What is the dividend status of AMGEN INC?
AMGEN INC (AMG.DE) has a dividend yield of 2.83%. The yearly dividend amount is currently 7.82.
What is the ChartMill technical and fundamental rating of AMG stock?
AMG.DE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the next earnings date for AMG stock?
AMGEN INC (AMG.DE) will report earnings on 2026-02-02, after the market close.
What is the ownership structure of AMGEN INC (AMG.DE)?
You can find the ownership structure of AMGEN INC (AMG.DE) on the Ownership tab.
AMG.DE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to AMG.DE. When comparing the yearly performance of all stocks, AMG.DE is one of the better performing stocks in the market, outperforming 82.7% of all stocks.
AMG.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AMG.DE. While AMG.DE has a great profitability rating, there are quite some concerns on its financial health.
AMG.DE Financial Highlights
Over the last trailing twelve months AMG.DE reported a non-GAAP Earnings per Share(EPS) of 18.89. The EPS increased by 13.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.47% | ||
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| Debt/Equity | 5.45 |
AMG.DE Forecast & Estimates
40 analysts have analysed AMG.DE and the average price target is 282.03 EUR. This implies a price decrease of -4.52% is expected in the next year compared to the current price of 295.4.
For the next year, analysts expect an EPS growth of 8.22% and a revenue growth 7.43% for AMG.DE